Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean M Devlin

Showing results (131-140 of 174) with videos related to

Pageof 18
Sort By:
Nature Communications|August 8, 2022
Unified classification and risk-stratification in Acute Myeloid LeukemiaYanis Tazi, Juan E Arango-Ossa, Yangyu Zhou, et al.
Haematologica|December 24, 2025
Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma : a multi-center propensity score-matched analysisRonit Marcus, Abraham Avigdor, Uri Greenbaum, et al.
Blood Cancer Journal|April 14, 2025
CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphomaAlejandro Luna, Sean M Devlin, Kai Rejeski, et al.
Blood Advances|August 15, 2025
Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphomaXavier Deschênes-Simard, Maria Bromberg, Sean M Devlin, et al.
JAMA Oncology|May 15, 2025
Barriers to Chimeric Antigen Receptor T-Cell TherapyYannis K Valtis, Kuo-Kai Chin, David Nemirovsky, et al.
British Journal of Haematology|May 12, 2024
Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profileRoni Shouval, Adam Goldman, Jessica R Flynn, et al.
Haematologica|June 20, 2024
Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in <I>de novo</I> large B-cell lymphoma and transformed low-grade B-cell lymphomaOhad Benjamini, Shalev Fried, Roni Shouval, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2021
Impact of <i>TP53</i> Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell TherapyRoni Shouval, Ana Alarcon Tomas, Joshua A Fein, et al.
Haematologica|December 8, 2018
Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemiaWenbin Xiao, Aaron D Goldberg, Christopher A Famulare, et al.
Haematologica|February 22, 2020
Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphomaRichard J Lin, Stephanie M Lobaugh, Martina Pennisi, et al.
Pageof 18

Showing results (131-140 of 174) with videos related to

Sort By:
Pageof 18
Nature Communications|August 8, 2022
Unified classification and risk-stratification in Acute Myeloid LeukemiaYanis Tazi, Juan E Arango-Ossa, Yangyu Zhou, et al.
Haematologica|December 24, 2025
Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma : a multi-center propensity score-matched analysisRonit Marcus, Abraham Avigdor, Uri Greenbaum, et al.
Blood Cancer Journal|April 14, 2025
CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphomaAlejandro Luna, Sean M Devlin, Kai Rejeski, et al.
Blood Advances|August 15, 2025
Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphomaXavier Deschênes-Simard, Maria Bromberg, Sean M Devlin, et al.
JAMA Oncology|May 15, 2025
Barriers to Chimeric Antigen Receptor T-Cell TherapyYannis K Valtis, Kuo-Kai Chin, David Nemirovsky, et al.
British Journal of Haematology|May 12, 2024
Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profileRoni Shouval, Adam Goldman, Jessica R Flynn, et al.
Haematologica|June 20, 2024
Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in <I>de novo</I> large B-cell lymphoma and transformed low-grade B-cell lymphomaOhad Benjamini, Shalev Fried, Roni Shouval, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2021
Impact of <i>TP53</i> Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell TherapyRoni Shouval, Ana Alarcon Tomas, Joshua A Fein, et al.
Haematologica|December 8, 2018
Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemiaWenbin Xiao, Aaron D Goldberg, Christopher A Famulare, et al.
Haematologica|February 22, 2020
Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphomaRichard J Lin, Stephanie M Lobaugh, Martina Pennisi, et al.
Pageof 18